fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 39. More products

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Zovirax (00886157). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Acyclovir

Form:

18 of 18 products shown

13 general benefit · 5 not a benefit

Apo-Acyclovir · DIN 02207621 · 200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Acyclovir · DIN 02207621 Manufacturer: Apotex Inc.; listing date 1998-12-31 Health Canada: Marketed since 1997-08-22 · brand APO-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02207621)

Source record
DIN 02207621: Apo-Acyclovir Raw flags: sec3=Y Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.3511; ministry $0.3511 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02207621 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43018
Interchangeable products
Mint-Acyclovir · DIN 02524708 · $0.3511 Mylan-Acyclovir · DIN 02242784 · $0.3511 Teva-Acyclovir · DIN 02285959 · $0.3511 Zovirax · DIN 00634506 · not recorded
Shortage status: resolved shortage (ended February 8, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02207621
Shortage record checked October 6, 2026

Mint-Acyclovir · DIN 02524708 · 200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Acyclovir · DIN 02524708 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2022-10-31 Health Canada: Marketed since 2022-07-15 · brand MINT-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02524708)

Source record
DIN 02524708: Mint-Acyclovir Raw flags: sec3=Y Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id MIN Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.3511; ministry $0.3511 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524708 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101372
Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511 Mylan-Acyclovir · DIN 02242784 · $0.3511 Teva-Acyclovir · DIN 02285959 · $0.3511 Zovirax · DIN 00634506 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524708
Shortage record checked October 6, 2026

Mylan-Acyclovir · DIN 02242784 · 200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mylan-Acyclovir · DIN 02242784 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2001-06-07 Health Canada: Marketed since 2010-02-12 · brand MYLAN-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mylan-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242784)

Source record
DIN 02242784: Mylan-Acyclovir Raw flags: sec3=Y Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id MYL Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.3511; ministry $0.3511 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242784 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66607
Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511 Mint-Acyclovir · DIN 02524708 · $0.3511 Teva-Acyclovir · DIN 02285959 · $0.3511 Zovirax · DIN 00634506 · not recorded
Shortage status: active shortage (reported September 8, 2026, estimated to end December 8, 2026, last updated September 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242784
Shortage record checked October 6, 2026

Teva-Acyclovir · DIN 02285959 · 200 mg · tablet

General benefitMarketed · checked November 16, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Acyclovir · DIN 02285959 Manufacturer: Teva Canada Limited; listing date 2008-01-15 Health Canada: Marketed since 2011-01-25 · brand TEVA-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02285959)

Source record
DIN 02285959: Teva-Acyclovir Raw flags: sec3=Y Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id TEV Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.3511; ministry $0.3511 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285959 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77144
Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511 Mint-Acyclovir · DIN 02524708 · $0.3511 Mylan-Acyclovir · DIN 02242784 · $0.3511 Zovirax · DIN 00634506 · not recorded
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285959
Shortage record checked October 6, 2026

Apo-Acyclovir · DIN 02207648 · 400 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Acyclovir · DIN 02207648 Manufacturer: Apotex Inc.; listing date 1998-12-31 Health Canada: Marketed since 1997-08-22 · brand APO-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02207648)

Source record
DIN 02207648: Apo-Acyclovir Raw flags: sec3=Y Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id APX Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.8890; ministry $0.8890 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02207648 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43019
Interchangeable products
Mint-Acyclovir · DIN 02524716 · $0.8890 Mylan-Acyclovir · DIN 02242463 · $0.8890 Teva-Acyclovir · DIN 02285967 · $0.8890 Zovirax · DIN 01911627 · not recorded
Shortage status: resolved shortage (ended October 10, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02207648
Shortage record checked October 6, 2026

Mint-Acyclovir · DIN 02524716 · 400 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Acyclovir · DIN 02524716 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2022-10-31 Health Canada: Marketed since 2022-07-15 · brand MINT-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02524716)

Source record
DIN 02524716: Mint-Acyclovir Raw flags: sec3=Y Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id MIN Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.8890; ministry $0.8890 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524716 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101373
Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890 Mylan-Acyclovir · DIN 02242463 · $0.8890 Teva-Acyclovir · DIN 02285967 · $0.8890 Zovirax · DIN 01911627 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524716
Shortage record checked October 6, 2026

Mylan-Acyclovir · DIN 02242463 · 400 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mylan-Acyclovir · DIN 02242463 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2001-06-07 Health Canada: Marketed since 2009-12-04 · brand MYLAN-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mylan-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242463)

Source record
DIN 02242463: Mylan-Acyclovir Raw flags: sec3=Y Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id MYL Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.8890; ministry $0.8890 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242463 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66188
Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890 Mint-Acyclovir · DIN 02524716 · $0.8890 Teva-Acyclovir · DIN 02285967 · $0.8890 Zovirax · DIN 01911627 · not recorded
Shortage status: anticipated shortage (last updated September 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242463
Shortage record checked October 6, 2026

Teva-Acyclovir · DIN 02285967 · 400 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Acyclovir · DIN 02285967 Manufacturer: Teva Canada Limited; listing date 2008-01-15 Health Canada: Marketed since 2011-01-25 · brand TEVA-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02285967)

Source record
DIN 02285967: Teva-Acyclovir Raw flags: sec3=Y Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id TEV Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.8890; ministry $0.8890 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285967 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77145
Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890 Mint-Acyclovir · DIN 02524716 · $0.8890 Mylan-Acyclovir · DIN 02242463 · $0.8890 Zovirax · DIN 01911627 · not recorded
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285967
Shortage record checked October 6, 2026

Apo-Acyclovir · DIN 02207656 · 800 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Acyclovir · DIN 02207656 Manufacturer: Apotex Inc.; listing date 1998-12-31 Health Canada: Marketed since 1997-08-22 · brand APO-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02207656)

Source record
DIN 02207656: Apo-Acyclovir Raw flags: sec3=Y Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id APX Source form: Tab; strength: 800mg Recorded listing: General benefit Source prices (unrounded): $1.2673; ministry $1.2673 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02207656 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43020
Interchangeable products
Mint-Acyclovir · DIN 02524724 · $1.2673 Mylan-Acyclovir · DIN 02242464 · $1.2673 Teva-Acyclovir · DIN 02285975 · $1.2673 Zovirax · DIN 01911635 · $1.2673
Shortage status: resolved shortage (ended February 8, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02207656
Shortage record checked October 6, 2026

Mint-Acyclovir · DIN 02524724 · 800 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Acyclovir · DIN 02524724 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2022-10-31 Health Canada: Marketed since 2022-07-15 · brand MINT-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02524724)

Source record
DIN 02524724: Mint-Acyclovir Raw flags: sec3=Y Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id MIN Source form: Tab; strength: 800mg Recorded listing: General benefit Source prices (unrounded): $1.2673; ministry $1.2673 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524724 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101374
Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673 Mylan-Acyclovir · DIN 02242464 · $1.2673 Teva-Acyclovir · DIN 02285975 · $1.2673 Zovirax · DIN 01911635 · $1.2673
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524724
Shortage record checked October 6, 2026

Mylan-Acyclovir · DIN 02242464 · 800 mg · tablet

General benefitMarketed · checked November 16, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Acyclovir · DIN 02242464 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2001-03-07 Health Canada: Marketed since 2009-12-04 · brand MYLAN-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mylan-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242464)

Source record
DIN 02242464: Mylan-Acyclovir Raw flags: sec3=Y Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id MYL Source form: Tab; strength: 800mg Recorded listing: General benefit Source prices (unrounded): $1.2673; ministry $1.2673 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242464 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66189
Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673 Mint-Acyclovir · DIN 02524724 · $1.2673 Teva-Acyclovir · DIN 02285975 · $1.2673 Zovirax · DIN 01911635 · $1.2673
Shortage status: resolved shortage (ended May 26, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242464
Shortage record checked October 6, 2026

Teva-Acyclovir · DIN 02285975 · 800 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Acyclovir · DIN 02285975 Manufacturer: Teva Canada Limited; listing date 2007-01-02 Health Canada: Marketed since 2011-01-25 · brand TEVA-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02285975)

Source record
DIN 02285975: Teva-Acyclovir Raw flags: sec3=Y Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id TEV Source form: Tab; strength: 800mg Recorded listing: General benefit Source prices (unrounded): $1.2673; ministry $1.2673 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285975 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77146
Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673 Mint-Acyclovir · DIN 02524724 · $1.2673 Mylan-Acyclovir · DIN 02242464 · $1.2673 Zovirax · DIN 01911635 · $1.2673
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285975
Shortage record checked October 6, 2026

Apo-Acyclovir Ointment · DIN 02477130 · 5% · Top Oint

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Apo-Acyclovir Ointment · DIN 02477130 Manufacturer: Apotex Inc.; listing date 2019-05-31 Health Canada: Marketed since 2019-03-14 · brand APO-ACYCLOVIR OINTMENT · ATC D06BB03 ACICLOVIR · form Ointment · route Topical · ingredients ACYCLOVIR 5 %/W/W · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477130)

Source record
DIN 02477130: Apo-Acyclovir Ointment Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840406002; group id 816; item number 1995; lccId None; manufacturer id APX Source form: Top Oint; strength: 5% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $12.3114; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477130 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96789
Interchangeable products
Taro-Acyclovir · DIN 02522306 · not recorded Zovirax · DIN 00569771 · not recorded
Shortage status: resolved shortage (ended August 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477130
Shortage record checked October 6, 2026

Taro-Acyclovir · DIN 02522306 · 5% · Top Oint

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Taro-Acyclovir · DIN 02522306 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-04-29 Health Canada: Marketed since 2022-02-25 · brand TARO-ACYCLOVIR · ATC D06BB03 ACICLOVIR · form Ointment · route Topical · ingredients ACYCLOVIR 5 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02522306)

Source record
DIN 02522306: Taro-Acyclovir Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840406002; group id 816; item number 1995; lccId None; manufacturer id TAR Source form: Top Oint; strength: 5% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $12.3114; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02522306 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101144
Interchangeable products
Apo-Acyclovir Ointment · DIN 02477130 · not recorded Zovirax · DIN 00569771 · not recorded
Shortage status: resolved shortage (ended June 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522306
Shortage record checked October 6, 2026

Zovirax · DIN 00569771 · 5% · Top Oint

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 00569771 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2020-12-22 · brand ZOVIRAX · ATC D06BB03 ACICLOVIR · form Ointment · route Topical · ingredients ACYCLOVIR 5 %/W/W · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zovirax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00569771)

Source record
DIN 00569771: Zovirax Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840406002; group id 816; item number 1995; lccId None; manufacturer id VAL Source form: Top Oint; strength: 5% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00569771 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4959
Interchangeable products
Apo-Acyclovir Ointment · DIN 02477130 · not recorded Taro-Acyclovir · DIN 02522306 · not recorded
Shortage status: resolved shortage (ended August 10, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00569771
Shortage record checked October 6, 2026

Zovirax · DIN 01911635 · 800 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2011-08-03 — choose a marketed DIN from the same-category list.Discontinued August 3, 2011 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2011-08-03 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2011-08-03 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 01911635 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Cancelled post market since 2011-08-03 · brand ZOVIRAX 800 · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01911635)

Source record
DIN 01911635: Zovirax Raw flags: sec3=Y Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id GSK Source form: Tab; strength: 800mg Recorded listing: General benefit Source prices (unrounded): $5.0692; ministry $1.2673 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01911635 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11632
Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673 Mint-Acyclovir · DIN 02524724 · $1.2673 Mylan-Acyclovir · DIN 02242464 · $1.2673 Teva-Acyclovir · DIN 02285975 · $1.2673
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911635
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 3, 2011 — choose a marketed DIN from the same-category list.

Zovirax · DIN 00634506 · 200 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-01-11 — choose a marketed DIN from the same-category list.Discontinued January 11, 2016 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-01-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-01-11 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 00634506 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Cancelled post market since 2016-01-11 · brand ZOVIRAX TAB 200MG · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zovirax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00634506)

Source record
DIN 00634506: Zovirax Raw flags: notABenefit=Y, sec3=Y Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id GSK Source form: Tab; strength: 200mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00634506 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7063
Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511 Mint-Acyclovir · DIN 02524708 · $0.3511 Mylan-Acyclovir · DIN 02242784 · $0.3511 Teva-Acyclovir · DIN 02285959 · $0.3511
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00634506
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 11, 2016 — choose a marketed DIN from the same-category list.

Zovirax · DIN 01911627 · 400 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-20 — choose a marketed DIN from the same-category list.Discontinued February 20, 2014 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-20 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-02-20 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 01911627 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Cancelled post market since 2014-02-20 · brand ZOVIRAX 400 · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zovirax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01911627)

Source record
DIN 01911627: Zovirax Raw flags: notABenefit=Y, sec3=Y Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id GSK Source form: Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01911627 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11420
Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890 Mint-Acyclovir · DIN 02524716 · $0.8890 Mylan-Acyclovir · DIN 02242463 · $0.8890 Teva-Acyclovir · DIN 02285967 · $0.8890
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911627
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 20, 2014 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D06BB, J05A, J05AB): coverage varies; not interchangeable

  • Ganciclovir (Cytovene): general benefit
  • Famciclovir (Famvir): limited Use 147, not a benefit
  • Remdesivir (Veklury): limited Use 722
  • Valganciclovir (Valcyte): limited Use 374, 568, 569, limited Use 571, 572, 573
  • Imiquimod (Taro-Imiquimod Pump): not a benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

50 more in the class list below

Valacyclovir

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Apo-Valacyclovir · DIN 02295822 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Valacyclovir · DIN 02295822 Manufacturer: Apotex Inc.; listing date 2008-08-28 Health Canada: Marketed since 2008-05-23 · brand APO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02295822)

Source record
DIN 02295822: Apo-Valacyclovir Raw flags: sec3=Y Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id APX Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.6198; ministry $0.6198 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295822 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78118
Interchangeable products
Auro-Valacyclovir · DIN 02405040 · $0.6198 Co Valacyclovir · DIN 02331748 · $0.6198 Jamp Valacyclovir · DIN 02440598 · $0.6198 Jamp-Valacyclovir · DIN 02441454 · $0.6198 Mylan-Valacyclovir · DIN 02351579 · $0.6198 PMS-Valacyclovir · DIN 02298457 · $0.6198 Riva-Valacyclovir · DIN 02316447 · $0.6198 Sandoz Valacyclovir · DIN 02347091 · $0.6198 Teva-Valacyclovir · DIN 02357534 · $0.6198 Valacyclovir · DIN 02442000 · $0.6198 Valacyclovir · DIN 02454645 · $0.6198 Valtrex · DIN 02219492 · $0.6198
Shortage status: shortage reported ended July 23, 2026 (report last updated July 23, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295822
Shortage record checked October 6, 2026

Auro-Valacyclovir · DIN 02405040 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Valacyclovir · DIN 02405040 Manufacturer: Auro Pharma Inc.; listing date 2013-07-30 Health Canada: Marketed since 2015-07-24 · brand AURO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02405040)

Source record
DIN 02405040: Auro-Valacyclovir Raw flags: sec3=Y Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id AUR Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.6198; ministry $0.6198 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02405040 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88988
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198 Co Valacyclovir · DIN 02331748 · $0.6198 Jamp Valacyclovir · DIN 02440598 · $0.6198 Jamp-Valacyclovir · DIN 02441454 · $0.6198 Mylan-Valacyclovir · DIN 02351579 · $0.6198 PMS-Valacyclovir · DIN 02298457 · $0.6198 Riva-Valacyclovir · DIN 02316447 · $0.6198 Sandoz Valacyclovir · DIN 02347091 · $0.6198 Teva-Valacyclovir · DIN 02357534 · $0.6198 Valacyclovir · DIN 02442000 · $0.6198 Valacyclovir · DIN 02454645 · $0.6198 Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended August 30, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02405040
Shortage record checked October 6, 2026

Jamp Valacyclovir · DIN 02440598 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Valacyclovir · DIN 02440598 Manufacturer: Jamp Pharma Corporation; listing date 2021-07-30 Health Canada: Marketed since 2021-04-13 · brand JAMP VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02440598)

Source record
DIN 02440598: Jamp Valacyclovir Raw flags: sec3=Y Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.6198; ministry $0.6198 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02440598 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92496
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198 Auro-Valacyclovir · DIN 02405040 · $0.6198 Co Valacyclovir · DIN 02331748 · $0.6198 Jamp-Valacyclovir · DIN 02441454 · $0.6198 Mylan-Valacyclovir · DIN 02351579 · $0.6198 PMS-Valacyclovir · DIN 02298457 · $0.6198 Riva-Valacyclovir · DIN 02316447 · $0.6198 Sandoz Valacyclovir · DIN 02347091 · $0.6198 Teva-Valacyclovir · DIN 02357534 · $0.6198 Valacyclovir · DIN 02442000 · $0.6198 Valacyclovir · DIN 02454645 · $0.6198 Valtrex · DIN 02219492 · $0.6198
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02440598
Shortage record checked October 6, 2026

Mylan-Valacyclovir · DIN 02351579 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Valacyclovir · DIN 02351579 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2010-07-20 Health Canada: Marketed since 2010-05-25 · brand MYLAN-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mylan-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02351579)

Source record
DIN 02351579: Mylan-Valacyclovir Raw flags: sec3=Y Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id MYL Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.6198; ministry $0.6198 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02351579 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83683
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198 Auro-Valacyclovir · DIN 02405040 · $0.6198 Co Valacyclovir · DIN 02331748 · $0.6198 Jamp Valacyclovir · DIN 02440598 · $0.6198 Jamp-Valacyclovir · DIN 02441454 · $0.6198 PMS-Valacyclovir · DIN 02298457 · $0.6198 Riva-Valacyclovir · DIN 02316447 · $0.6198 Sandoz Valacyclovir · DIN 02347091 · $0.6198 Teva-Valacyclovir · DIN 02357534 · $0.6198 Valacyclovir · DIN 02442000 · $0.6198 Valacyclovir · DIN 02454645 · $0.6198 Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended April 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351579
Shortage record checked October 6, 2026

PMS-Valacyclovir · DIN 02298457 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Valacyclovir · DIN 02298457 Manufacturer: Pharmascience Inc.; listing date 2008-08-28 Health Canada: Marketed since 2008-05-16 · brand PMS-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298457)

Source record
DIN 02298457: PMS-Valacyclovir Raw flags: sec3=Y Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id PMS Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.6198; ministry $0.6198 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298457 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78376
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198 Auro-Valacyclovir · DIN 02405040 · $0.6198 Co Valacyclovir · DIN 02331748 · $0.6198 Jamp Valacyclovir · DIN 02440598 · $0.6198 Jamp-Valacyclovir · DIN 02441454 · $0.6198 Mylan-Valacyclovir · DIN 02351579 · $0.6198 Riva-Valacyclovir · DIN 02316447 · $0.6198 Sandoz Valacyclovir · DIN 02347091 · $0.6198 Teva-Valacyclovir · DIN 02357534 · $0.6198 Valacyclovir · DIN 02442000 · $0.6198 Valacyclovir · DIN 02454645 · $0.6198 Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended September 11, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298457
Shortage record checked October 6, 2026

Riva-Valacyclovir · DIN 02316447 · 500 mg · tablet

General benefitMarketed · checked November 17, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Valacyclovir · DIN 02316447 Manufacturer: Laboratoire Riva Inc.; listing date 2025-08-29 Health Canada: Marketed since 2008-10-27 · brand RIVA-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Laboratoire riva inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Riva-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02316447)

Source record
DIN 02316447: Riva-Valacyclovir Raw flags: sec3=Y Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id RIA Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.6198; ministry $0.6198 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02316447 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80195
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198 Auro-Valacyclovir · DIN 02405040 · $0.6198 Co Valacyclovir · DIN 02331748 · $0.6198 Jamp Valacyclovir · DIN 02440598 · $0.6198 Jamp-Valacyclovir · DIN 02441454 · $0.6198 Mylan-Valacyclovir · DIN 02351579 · $0.6198 PMS-Valacyclovir · DIN 02298457 · $0.6198 Sandoz Valacyclovir · DIN 02347091 · $0.6198 Teva-Valacyclovir · DIN 02357534 · $0.6198 Valacyclovir · DIN 02442000 · $0.6198 Valacyclovir · DIN 02454645 · $0.6198 Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended January 17, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316447
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D06BB, J05A, J05AB): coverage varies; not interchangeable

  • Ganciclovir (Cytovene): general benefit
  • Famciclovir (Famvir): limited Use 147, not a benefit
  • Remdesivir (Veklury): limited Use 722
  • Valganciclovir (Valcyte): limited Use 374, 568, 569, limited Use 571, 572, 573
  • Imiquimod (Taro-Imiquimod Pump): not a benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

50 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE 08:18 Antivirals

GANCICLOVIR SODIUM

· 1 products · General benefit · strengths: 500mg/Vial · Pd Inj-10mL Pk

FAMCICLOVIR

· 8 products · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 147 (2) · strengths: 125mg, 250mg, 500mg · Tab

REMDESIVIR

· 1 products · Limited Use, codes 722 · strengths: 100mg/vial · Pd for Sol-100mg Vial Pk

VALGANCICLOVIR

· 6 products · Limited Use, codes 571, 572, 573 (2), Limited Use, codes 374, 568, 569 (4) · strengths: 50mg/mL, 450mg · Pd for Oral Sol-100mL Pk, Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:18 and 41 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives

Other drugs in the same formulary class (84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS) and how they are covered

Matched class: 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, DIMETHICONE., FLUOROURACIL, FUSIDIC ACID, HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE & TAZAROTENE, ISOPROPYL MYRISTATE, ISOTRETINOIN, METRONIDAZOLE & NYSTATIN, MICONAZOLE NITRATE, MOMETASONE FUROATE, MUPIROCIN CALCIUM, PERMETHRIN, PYRETHRINS & PIPERONYL BUTOXIDE, SILVER SULFADIAZINE, SODIUM FUSIDATE, TERBINAFINE HCL, ZINC SULFATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, CLOTRIMAZOLE, COLLAGENASE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, KETOCONAZOLE, METRONIDAZOLE, MUPIROCIN, NYSTATIN, TERCONAZOLE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

HALOBETASOL PROPIONATE & TAZAROTENE

· 1 products · General benefit · strengths: 0.01% & 0.045% · Lot

BIMEKIZUMAB

· 4 products · Limited Use, codes 641 · strengths: 160mg/mL, 320mg/2mL · Inj Sol-1mL Pref Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-2mL Pref Autoinj (Preservative-Free), Inj Sol-2mL Pref Syr (Preservative-Free)

GUSELKUMAB

· 2 products · Limited Use, codes 658 · strengths: 100mg/mL · Inj Sol-1mL Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free)

TAZAROTENE

· 1 products · Limited Use, codes 636 · strengths: 0.045% w/w · Lot

TILDRAKIZUMAB

· 2 products · Limited Use, codes 629 · strengths: 100mg/mL · Inj Sol-1mL Pref Pen (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:00 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:04 and 53 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: herpes zoster
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. FAMCICLOVIR · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 147 (2) INDICATIONS AND CLINICAL USE FAMVIR® (famciclovir) tablets are indicated : • for the treatment of acute herpes zoster (shingles) • for the treatment or suppression of recurrent episodes of genital herpes in immunocompetent adults. PM: https://pdf.hres.ca/dpd_pm/00078599.PDF; date FEB 13, 2025; DIN 02177102; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Zovirax (acyclovir 5%) cream is indicated for the topical management of initial episodes of genital herpes simplex infections. The prophylactic use of this preparation has not been established. Zovirax (acyclovir 5%) ointment is for the management of initial episodes of genital herpes simplex infections. It is also indicated in the management of non-life-threatening cutaneous herpes simplex virus infections in immunocompromised patients. The prophylactic use of this preparation has not been established. Pr ZOVIRAX ® Product Monograph Page 2 of 32 In the treatment of genital herpes, appropriate examinations should be performed to rule out other sexually transmitted diseases. Therapy should begin as early as possible after the start of an infection. Whereas cutaneous lesions associated with herpes simplex infections are often pathognomonic, TZANCK smears prepared from lesion exudate or scrapings may assist in the diagnosis. Positive cultures for herpes simplex virus offer the only absolute means for confirmation of the diagnosis. These indications are based on … https://pdf.hres.ca/dpd_pm/00059349.PDF PM date: December 22, 2020 Source product: ZOVIRAX; DIN 00569771; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications VALTREX, valacyclovir tablets (as valacyclovir hydrochloride), is indicated: • For the treatment of herpes zoster (shingles) in adult patients. • For the treatment or suppression of genital herpes in immunocompetent adult patients and for the suppression of recurrent genital herpes in HIV infected adult patients. • To reduce the risk of transmission of genital herpes with the use of suppressive therapy in adult patients. Safer sex practices should be used with suppressive therapy. • For the treatment of cold sores (herpes labialis) in adult patients and adolescent patients ≥ 12 years of age. 1.1. Pediatrics Pediatrics (<12 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (>65 years of age): Use in the geriatric population may be associated with differences in safety due to age-related changes in renal function and a brief discussion can be found in the appropriate sections (see 7.Warnings and Precautions, Renal) https://pdf.hres.ca/dpd_pm/00083875.PDF PM date: 2026-03-13 Source product: VALTREX; DIN 02219492; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Mylan-Acyclovir · DIN 02242784 Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-12-08, last updated 2026-09-09); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242784

Check this DIN again

Teva-Acyclovir · DIN 02285959 Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285959

Check this DIN again

Teva-Acyclovir · DIN 02285967 Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285967

Check this DIN again

Teva-Acyclovir · DIN 02285975 Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285975

Check this DIN again

Apo-Valacyclovir · DIN 02295822 Shortage status: shortage reported ended 2026-07-23 (report last updated 2026-07-23); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295822

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Apo-Acyclovir Ointment, Taro-Acyclovir, Zovirax: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026